EYESW (Second Sight Medical Products) EBITDA: $-9.08 Mil (TTM As of Jun. 2022)


What is Second Sight Medical Products EBITDA?

Second Sight Medical Products EYESW EBITDA is $-9.08 Mil as of Jun. 2022. The stock has 1 warning sign investors should review.

Second Sight Medical Products's EBITDA for the three months ended in Jun. 2022 was $-3.11 Mil. Its EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 was $-9.08 Mil.

During the past 3 years, the average EBITDA Growth Rate was 36.20% per year. During the past 5 years, the average EBITDA Growth Rate was 22.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA Growth Rate using EBITDA data.

During the past 10 years, the highest 3-Year average EBITDA Growth Rate of Second Sight Medical Products was 36.20% per year. The lowest was -22.90% per year. And the median was -0.30% per year.

Second Sight Medical Products's EBITDA per Share for the three months ended in Jun. 2022 was $0.00. Its EBITDA per share for the trailing twelve months (TTM) ended in Jun. 2022 was $0.00.

During the past 3 years, the average EBITDA per Share Growth Rate was 79.80% per year. During the past 5 years, the average EBITDA per Share Growth Rate was 50.40% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBITDA per share growth rate using EBITDA per Share data.

During the past 10 years, the highest 3-Year average EBITDA per Share Growth Rate of Second Sight Medical Products was 79.80% per year. The lowest was -95.30% per year. And the median was 22.40% per year.

Second Sight Medical Products  (NAS:EYESW) EBITDA Explanation

EBITDA is a cash flow measure that ignores changes in working capital. EBITDA minus Depreciation, and Amortization (DA) equals Operating Income. Operating Income is profit before interest and taxes. Of course, Interest and taxes need to be paid.

While depreciation and amortization expenses do not need to be paid in cash, assets - especially tangible assets - do need to be replaced over time. EBITDA is not a measure of profit in any sense. EBITDA is a measure of cash generation by a business where the uses of that cash may be more or less discretionary depending on the nature of the business.

The EBITDA of a TV station is largely discretionary. Owners may use much of the EBITDA generated by a TV station as they see fit. The EBITDA of a railroad is largely non-discretionary. Owners must use much of the EBITDA generated by a railroad to replace the physical assets of the railroad or the business will literally fall apart over time.

EBITDA can be thought of as the cash a business generates that is available to:

Add more inventory
Add more receivables
Replace property, plant, and equipment
Add more property, plant, and equipment
Pay interest
Pay taxes
And finally: pay owners

EBITDA is widely used in financial analysis because Depreciation and Amortization are not present day cash expenses.. Depreciation and amortization are the spreading out of the costs of assets over the time in which those assets provide benefits. Today's depreciation and amortization expenses relate to assets bought in the past. The assets being expensed may or may not need to be replaced in the future. And the cost to replace the assets may be more or less than it was in the past. For this reason, the depreciation and amortization expenses a company records in the present year may have no relationship to the actual cash costs needed to maintain its assets in future years.

A company's depreciation expense depends on both its expectations about the assets it owns and its choice of accounting methods. Two companies owning identical assets may have different depreciation expenses because they have different expectations about the useful lives of those assets and because they make different accounting choices.

Analysts use EBITDA to remove this element of personal choice from a company's accounting statements. The use of EBITDA is an attempt to make the results of different companies more comparable and uniform.


Be Aware

Although depreciation is not a cash cost it is a real business cost because the company has to pay for the fixed assets when they purchase them. Both Warren Buffett and Charlie Munger hate the idea of EBITDA because in this calculation, depreciation is not counted as an expense.

EBITDA over Revenue is a good metric for comparing the operating efficiencies between companies because EBITDA is less vulnerable to companies' accounting choices. For this reason, EBITDA is used in ranking the Predictability of Companies. Also Price-to-EBITDA is sometimes used in valuations.


Second Sight Medical Products EBITDA Related Terms


Second Sight Medical Products EBITDA Historical Data

* Premium members only.

The historical data trend for Second Sight Medical Products's EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Second Sight Medical Products EBITDA Chart

Second Sight Medical Products Annual Data
Trend Dec12 Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only -28.15 -34.19 -30.20 -12.50 -8.86

Second Sight Medical Products Quarterly Data
Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22
EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.28 -2.49 -1.28 -2.20 -3.11

EYESW vs SONX, LUCD, LHDX: EBITDA Comparison

For the Medical Devices subindustry, Second Sight Medical Products's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Second Sight Medical Products EV-to-EBITDA vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Second Sight Medical Products's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Second Sight Medical Products's EV-to-EBITDA falls into.


Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.

Second Sight Medical Products's EBITDA for the fiscal year that ended in Dec. 2021 is calculated as

Second Sight Medical Products's EBITDA was directly provided by GuruFocus' data source Morningstar. For the fiscal year ended in Dec. 2021, Second Sight Medical Products's EBITDA was $-8.86 Mil.

Second Sight Medical Products's EBITDA for the quarter that ended in Jun. 2022 is calculated as

Second Sight Medical Products's EBITDA was directly provided by GuruFocus' data source Morningstar. For the quarter ended in Jun. 2022, Second Sight Medical Products's EBITDA was $-3.11 Mil.

EBITDA for the trailing twelve months (TTM) ended in Jun. 2022 adds up the quarterly data reported by the company within the most recent 12 months, which was $-9.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Sometimes companies may have already deducted Depreciation and Amortization from Gross Profit. In this case Depreciation and Amortization needs to be added back when calculating EBITDA.

Frequently Asked Questions Learn more about EBITDA →
What does a EBITDA of $-9.08 Mil mean?
Second Sight Medical Products (EYESW) has a EBITDA of $-9.08 Mil as of Jun. 2022. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Second Sight Medical Products.
Is Second Sight Medical Products' EBITDA too high?
Second Sight Medical Products' current EBITDA is $-9.08 Mil.
How does Second Sight Medical Products' EBITDA compare to SONX and LUCD?
Second Sight Medical Products' EBITDA of $-9.08 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA for a Medical Devices & Instruments company?
A good EBITDA depends on the Medical Devices & Instruments industry context. However, EBITDA should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA mean?
A high EBITDA can signal that a stock is expensive relative to its fundamentals. Ebitda is the difference between operating revenue and operating expenses not including depreciation and amortization. View historical data on Second Sight Medical Products. Second Sight Medical Products's current EBITDA is $-9.08 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Second Sight Medical Products stock overvalued right now?
Second Sight Medical Products (EYESW) has a current EBITDA of $-9.08 Mil. The current EBITDA is $-9.08 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA calculated?
EBITDA is calculated from a company's financial statements. For Second Sight Medical Products (EYESW), the current EBITDA is $-9.08 Mil as of Jun. 2022. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Second Sight Medical Products Business Description

Address 13170 Telfair Avenue, Sylmar, CA, USA, 91342
Second Sight Medical Products Inc develops, manufactures, and markets implantable prosthetic devices to create an artificial form of useful vision for blind individuals. The company's product Argus II System treats outer retinal degenerations, such as Retinitis Pigmentosa, often referred to as RP. The company generates revenue from the sale of its Argus II retinal prosthesis systems, which include the implant and external components. Geographically, the company operates in the United States, Italy, China, and of which key revenue is derived from the United States.